title: [When should bisphosphonate treatment be discontinued?].
authors.affiliation: Endokrinologisk avdeling, Oslo universitetssykehus, Norway. e.f.eriksen@medisin.uio.no
authors.forename: Erik Fink
authors.initials: EF
authors.lastname: Eriksen
authors.forename: Johan
authors.initials: J
authors.lastname: Halse
mesh_terms: D019386:Alendronate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology; D004164:Diphosphonates / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate